Skip to main content

Insulet

Insulet Corporation is an American medical device company that develops, manufactures, and markets tubeless continuous insulin delivery systems for people with diabetes. The company operates through reportable business segments comprising the Omnipod System segment and the Drug Delivery segment. Its flagship product is the Omnipod Insulin Management System, a wearable, tubeless, waterproof insulin pump that delivers continuous subcutaneous insulin infusion. Principal revenue drivers consist of high-volume sales of disposable wearable Omnipod Pods, personal diabetes manager (PDM) controllers, and automated insulin delivery software. Insulet serves global healthcare end markets including endocrinology clinics, pediatric diabetes centers, specialty pharmacies, home medical equipment suppliers, and diabetes patients across North America and Europe. The corporation holds a market-leading position as the primary manufacturer of wearable tubeless continuous insulin infusion devices globally. Headquartered in Acton, Massachusetts, the company's common stock is publicly listed on the Nasdaq Global Select Market under the ticker symbol PODD and is included in the S&P 500 index.

20 of the funds FundTelligence covers report a position in Insulet.

Legal name
Insulet Corp.
Sector
Health Care
Country
United States
Funds holding it
20
Exposure themes
Diabetes Technology, Insulin Delivery, Obesity & Metabolic Health

Funds holding Insulet

Showing the 8 largest of 20 funds holding it.

Loading...